To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3494 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-02

Study Completion Date

2022-05-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chemotherapy-induced thrombocytopenia (CIT) is a common hematological toxicity in patients with solid tumors undergo chemotherapy, which can increase the risk of bleeding, prolong hospital stay, increase medical costs, and even lead to death in severe cases. The incidence and severity of CIT varies among different chemotherapy regimens. Recombinant human interleukin-11 (rhIL-11) and recombinant human thrombopoietin (rhTPO) have been approved for the treatment of chemotherapy-induced thrombocytopenia.

Tumor patients are at high risk for venous thromboembolism (VTE). In the clinical study of rhIL-11, it was found that the administration of rhIL-11 in healthy subjects caused an increase in the plasma concentration of vWF factor in the form of normal mults. The application of rhIL-11 in patients with myeloid leukemia can increase the concentration of α2 globulin, fibrinogen and prothrombin time. However, there have been no large-scale clinical studies at home and abroad to evaluate whether platelet raising therapy will increase the risk of thrombosis in chemotherapy patients with solid tumor. This study is aimed to evaluate the efficacy and safety of platelet upwelling therapy in patients with solid tumors undergoing chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Eltrombopag for Chemotherapy-induced Thrombocytopenia

NCT04600960

Chemotherapy-induced Thrombocytopenia Eltrombopag

RECRUITING PHASE2

Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury

NCT05411705

Cancer Treatment Induced Thrombocytopenia

RECRUITING PHASE4

Herombopag for Chemotherapy-induced Thrombocytopenia

NCT05236582

Chemotherapy-induced Thrombocytopenia Herombopag

RECRUITING PHASE2

Avatrombopag for Chemotherapy-induced Thrombocytopenia

NCT05218226

Chemotherapy-induced Thrombocytopenia Avatrombopag

RECRUITING PHASE2

Hetrombopag for the Thrombocytopenia Induced by Concurrent Chemoradiotherapy

NCT06433830

Thrombocytopenia Radiotherapy Side Effect

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chemotherapy-induced Thrombocytopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Recombinant Human Interleukin-11 for Injection

received rhIL-11 injection for at least 5 consecutive days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

rhIL-11

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with pathological diagnosis of solid tumors or lymphomas.
* Have received chemotherapy.
* Diagnosed of CIT.
* Continuous use of platelet raising drugs for at least 5 days.

Exclusion Criteria

* Thrombocytopenia caused other than chemotherapy, including but not limited to: traditional Chinese medicine, congenital platelet disease, etc.
* The basic value of platelet count is continuously higher than 300×10\^9/L.
* Those without blood routine or coagulation function data.
* Those who received non-chemotherapy drugs that may cause thrombocytopenia, such as sulfonamides.
* Pseudothrombocytopenia due to Ethylenediamine tetraacetic acid (EDTA) as an anticoagulant in test samples.

Eligible Sex

ALL

Accepts Healthy Volunteers

No